Close Menu

Trovagene

Owlstone Medical said this week that it has initiated the Pan Cancer trial for Early Detection of Cancer in Breath, a "large-scale clinical study" that will evaluate the use of Owlstone's Breath Biopsy platform for the early detection of multiple cancer types.

HTG Molecular Diagnostics has amended and restated an IVD test development and component supply agreement with Illumina to extend the agreement term and increase the number of in vitro diagnostic test kits that may be developed using Illumina’s sequencing technology.

The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.

The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.

The company believes that the reduction in staff and marketing costs for its testing services will reduce its annual pre-tax expenses by about $4 million.